LLY vs VSTM: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LLY and VSTM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LLY and VSTM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.

Full LLY guide

Verastem Oncology is a Needham, Massachusetts biotech focused on the RAS/MAPK pathway, the signaling chain that is mutated in roughly a third of human cancers. Its first approved product, AVMAPKI FAKZYNJA CO-PACK (avutometinib, a RAF/MEK inhibitor, taken with defactinib, a FAK inhibitor), won FDA accelerated approval in May 2025 for adults with recurrent KRAS-mutated low-grade serous ovarian cancer (LGSOC) who have had prior systemic therapy. Product sales are now the main source of revenue. The company also collects occasional milestone payments from Secura Bio, which bought its earlier drug COPIKTRA, and it has a royalty financing deal with Oberland Capital tied to future product sales.

Full VSTM guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.
• VSTM drivers: VS-7375 in KRAS G12D pancreatic cancer; The ovarian cancer launch ramp.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: LLY trades at a premium valuation (about 42x trailing and 27x forward earnings, and roughly 14x sales, as of October 2026), so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. For VSTM, the clearest risk is that VS-7375's early results do not hold up.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick LLY if you believe its drivers more; VSTM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LLY and VSTM guides.

LLY. At about $1,266 a share on October 16, 2026, Eli Lilly is valued near $1.13 trillion, roughly 42x trailing earnings and 27x the roughly $47.48 in EPS analysts expect for 2027. That premium rests on revenue growth near 48% in the latest quarter and margins (about 54% operating) that few drugmakers have reached. The debate centers on how large and durable the incretin market proves, how oral therapies such as Foundayo change it, and how Novo Nordisk and new entrants shape pricing; the October 29 third-quarter report (consensus about $7.16 EPS on $22.45 billion revenue) is the next data point.

VSTM. At roughly $1 billion in market value against ~$87.5 million of trailing revenue, about 12 times sales, the market is pricing Verastem mostly on VS-7375 rather than on its ovarian franchise. Price-to-earnings multiples do not apply while the company loses money, and the trailing revenue figure is flattered by a one-time $15 million milestone. The most useful lenses are cash runway, the pace of product sales growth, and how the pipeline compares with rivals. The October offering added ~30.9 million shares plus pre-funded warrants, a meaningful increase on a share base of roughly 100 million earlier in 2026.

Headline figures (approximate, October 2026): LLY shows revenue (ttm) ~$79.7 billion, q2 2026 revenue ~$23.0 billion (up ~48% YoY), q2 2026 eps $8.38 vs ~$6.58 est., gross / operating margin (ttm) ~83% / ~54%; VSTM shows revenue (ttm) ~$87.5M (incl. $15M COPIKTRA milestone), product revenue (q2 2026) ~$25.1M (Q1: ~$18.7M), net loss (q2 2026) ~$34.7M ($0.35/share), cash (june 30, 2026, pre-offering) ~$136.4M (~$201M pro forma).

LLY and VSTM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LLY and VSTM exposure against your real portfolio. It is not an investment adviser.